Profil
Israel Rios worked as a Director of Clinical Research at Bristol Myers Squibb Co. from 1978 to 1984, then as a Director of Anti Infective Clinical Research at Marion Merrell Dow, Inc. from 1984 to 1993.
He then worked as a Vice President of Oncology Development at Berlex, Inc. from 1993 to 2002, and as a Vice President of Clinical Affairs at Dendreon Corp.
from 2003 to 2005.
Later, he worked as a Chief Medical Officer and SVP of Medical Affairs at SciClone Pharmaceuticals LLC from 2009 to 2012.
Dr. Rios earned a doctorate degree from the Central University of Venezuela.
Anciens postes connus de Israel Rios
| Sociétés | Poste | Fin |
|---|---|---|
| SCICLONE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 06/04/2012 |
| DENDREON CORPORATION | Directeur Technique/Scientifique/R&D | 01/01/2005 |
Berlex, Inc.
 Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Corporate Officer/Principal | 01/01/2002 |
| Marion Merrell Dow, Inc. | Corporate Officer/Principal | 01/01/1993 |
| BRISTOL-MYERS SQUIBB COMPANY | Directeur Technique/Scientifique/R&D | 01/01/1984 |
Formation de Israel Rios
| Central University of Venezuela | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
| Marion Merrell Dow, Inc. | Health Technology |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Health Technology |
